company background image
TG4 logo

Oxurion DB:TG4 Stock Report

Last Price

€0.0001

Market Cap

€575.4k

7D

0%

1Y

n/a

Updated

23 Mar, 2024

Data

Company Financials

TG4 Stock Overview

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally.

TG4 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Oxurion NV Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oxurion
Historical stock prices
Current Share Price€0.0001
52 Week High€0.0073
52 Week Low€0.0001
Beta0.51
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

TG4DE BiotechsDE Market
7D0%4.5%1.4%
1Yn/a34.0%7.5%

Return vs Industry: Insufficient data to determine how TG4 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how TG4 performed against the German Market.

Price Volatility

Is TG4's price volatile compared to industry and market?
TG4 volatility
TG4 Average Weekly Movement27.9%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: TG4 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TG4's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199120Pascal Ghosonhttps://www.oxurion.com

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME.

Oxurion NV Fundamentals Summary

How do Oxurion's earnings and revenue compare to its market cap?
TG4 fundamental statistics
Market cap€575.40k
Earnings (TTM)-€27.82m
Revenue (TTM)€515.00k

1.1x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TG4 income statement (TTM)
Revenue€515.00k
Cost of Revenue€437.00k
Gross Profit€78.00k
Other Expenses€27.90m
Earnings-€27.82m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0048
Gross Margin15.15%
Net Profit Margin-5,402.72%
Debt/Equity Ratio-114.6%

How did TG4 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.